Randomised clinical trial of the effects of prolonged-release melatonin, temazepam and zolpidem on slow-wave activity during sleep in healthy people

Journal of Psychopharmacology

Volumn 29, Issue 7, 2015, Pages 764-776

  Arbon, Emma L ^a   Knurowska, Malgorzata ^b   Dijk, Derk Jan ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

EEG; Prolonged release melatonin; slow wave activity; temazepam; zolpidem

Indexed keywords

MELATONIN; PLACEBO; TEMAZEPAM; ZOLPIDEM; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; DELAYED RELEASE FORMULATION; HYPNOTIC SEDATIVE AGENT; PYRIDINE DERIVATIVE;

ADULT; ANXIETY DISORDER; ARTICLE; ASTHENIA; BALANCE DISORDER; BODY TEMPERATURE DISORDER; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISORIENTATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXCRETION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RELEASE; ELECTROENCEPHALOGRAPHY; FATIGUE; FEMALE; HUMAN; HUMAN EXPERIMENT; INFRARED SPECTROSCOPY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; NAUSEA; NIGHT SLEEP; NIGHTMARE; NONREM SLEEP; NORMAL HUMAN; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLOW BRAIN WAVE; SLOW WAVE SLEEP; SOMNOLENCE; URINARY EXCRETION; XEROSTOMIA; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; SLEEP;

CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; FEMALE; GABA MODULATORS; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MELATONIN; MIDDLE AGED; POLYSOMNOGRAPHY; PYRIDINES; SLEEP; TEMAZEPAM;

EID: 84934968300     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881115581963     Document Type: Article

References (46)

1. Aeschbach D, Dijk DJ, Borbely AA. Dynamics of EEG spindle frequency activity during extended sleep in humans: Relationship to slow-wave activity and time of day. Brain Res. 1997 ; 748: 131-136
2. Aeschbach D, Dijk DJ, Trachsel L, et al. Dynamics of slow-wave activity and spindle frequency activity in the human sleep EEG: Effect of midazolam and zopiclone. Neuropsychopharmacology. 1994 ; 11: 237-244
3. Aeschbach D, Lockyer BJ, Dijk DJ, et al. Use of transdermal melatonin delivery to improve sleep maintenance during daytime. Clin Pharmacol Ther. 2009 ; 86: 378-382
4. Akerstedt T, Gillberg M. Subjective and objective sleepiness in the active individual. Int J Neurosci. 1990 ; 52: 29-37
5. Arendt J, Rajaratnam SM. Melatonin and its agonists: An update. Brit J Psychiatry. 2008 ; 193: 267-269
6. Bastien CH, Leblanc M, Carrier J, et al. Sleep EEG power spectra, insomnia, and chronic use of benzodiazepines. Sleep. 2003 ; 26: 313-317
7. Bettica P, Squassante L, Groeger JA, et al. Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology. 2012 ; 37: 1224-1233
8. Brunner DP, Dijk DJ, Munch M, et al. Effect of zolpidem on sleep and sleep EEG spectra in healthy young men. Psychopharmacology. 1991 ; 104: 1-5
9. Buysse DJ, Reynolds CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res. 1989 ; 28: 193-213
10. Cajochen C, Krauchi K, Mori D, et al. Melatonin and S-20098 increase REM sleep and wake-up propensity without modifying NREM sleep homeostasis. Am J Physiol. 1997 ; 272: R1189 - R1196
11. Cajochen C, Krauchi K, Wirz-Justice A. Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol. 2003 ; 15: 432-437
12. Carocci A, Catalano A, Sinicropi MS. Melatonergic drugs in development. Clin Pharmacol. 2014 ; 6: 127-137
13. Dijk DJ. Slow-wave sleep deficiency and enhancement: Implications for insomnia and its management. World J Biol Psychiatry. 2010 ; 11: S22 - S28
14. Dijk DJ, Czeisler CA. Contribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalographic slow waves, and sleep spindle activity in humans. J Neurosci. 1995 ; 15: 3526-3538
15. Dijk DJ, Beersma DG, Daan S, et al. Effects of seganserin, a 5-HT2 antagonist, and temazepam on human sleep stages and EEG power spectra. Eur J Pharmacol. 1989 ; 171: 207-218
16. Dijk DJ, Brunner DP, Beersma DG, et al. Electroencephalogram power density and slow wave sleep as a function of prior waking and circadian phase. Sleep. 1990a ; 13: 430-440
17. Dijk DJ, Brunner DP, Borbely AA. Time course of EEG power density during long sleep in humans. Am J Physiol. 1990b ; 258: R650 - R661
18. Dijk DJ, Hayes B, Czeisler CA. Dynamics of electroencephalographic sleep spindles and slow wave activity in men: Effect of sleep deprivation. Brain Res. 1993 ; 626: 190-199
19. Dijk DJ, Roth C, Landolt HP, et al. Melatonin effect on daytime sleep in men: Suppression of EEG low frequency activity and enhancement of spindle frequency activity. Neurosci Lett. 1995 ; 201: 13-16
20. Dijk DJ, Shanahan TL, Duffy JF, et al. Variation of electroencephalographic activity during non-rapid eye movement and rapid eye movement sleep with phase of circadian melatonin rhythm in humans. J Physiol. 1997 ; 505: 851-858
21. Ebert B, Wafford KA, Deacon S. Treating insomnia: Current and investigational pharmacological approaches. Pharmacol Ther. 2006 ; 112: 612-629
22. Hajak G, Lemme K, Zisapel N. Lasting treatment effects in a postmarketing surveillance study of prolonged-release melatonin. Int Clin Psychopharmacol. 2015 ; 30: 36-42
23. Iber C, Ancoli-Israel S, Chesson A, et al The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications. Westchester, Illinois: American Academy of Sleep Medicine ; 2007 :
24. Lancel M. Role of GABAA receptors in the regulation of sleep: Initial sleep responses to peripherally administered modulators and agonists. Sleep. 1999 ; 22: 33-42
25. Landolt HP, Dijk DJ, Achermann P, et al. Effect of age on the sleep EEG: Slow-wave activity and spindle frequency activity in young and middle-aged men. Brain Res. 1996 ; 738: 205-212
26. Le Bon O, Neu D, Berquin Y, et al. Ultra-slow delta power in chronic fatigue syndrome. Psychiatry Res. 2012 ; 200: 742-747
27. Lemoine P, Zisapel N. Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia. Expert Opin Pharmacother. 2012 ; 13: 895-905
28. Lemoine P, Garfinkel D, Laudon M, et al. Prolonged-release melatonin for insomnia - an open-label long-term study of efficacy, safety, and withdrawal. Ther Clin Risk Manag. 2011 ; 7: 301-311
29. Lemoine P, Nir T, Laudon M, et al. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res. 2007 ; 16: 372-380
30. Luthringer R, Minot R, Toussaint M, et al. All-night EEG spectral analysis as a tool for the prediction of clinical response to antidepressant treatment. Biol Psychiatry. 1995 ; 38: 98-104
31. Luthringer R, Muzet M, Zisapel N, et al. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol. 2009 ; 24: 239-249
32. Merica H, Blois R, Gaillard JM. Spectral characteristics of sleep EEG in chronic insomnia. Eur J Neurosci. 1998 ; 10: 1826-1834
33. Otmani S, Demazieres A, Staner CJ, et al. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol. 2008 ; 23: 693-705
34. Rajaratnam SM, Middleton B, Stone BM, et al. Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in extended sleep opportunities in humans. J Physiol. 2004 ; 561: 339-351
35. Riemann D, Spiegelhalder K, Espie C, et al. Chronic insomnia: Clinical and research challenges-an agenda. Pharmacopsychiatry. 2011 ; 44: 1-14
36. Rudolph U, Knoflach F. Beyond classical benzodiazepines: Novel therapeutic potential of GABAA receptor subtypes. Nat Rev Drug Dis. 2011 ; 10: 685-697
37. Saper CB, Cano G, Scammell TE. Homeostatic, circadian, and emotional regulation of sleep. J Comp Neurol. 2005 ; 493: 92-98
38. Srinivasan V, Pandi-Perumal SR, Trahkt I, et al. Melatonin and melatonergic drugs on sleep: Possible mechanisms of action. Int J Neurosci. 2009 ; 119: 821-846
39. Stone BM, Turner C, Mills SL, et al. Hypnotic activity of melatonin. Sleep. 2000 ; 23: 663-669
40. Wade AG, Crawford G, Ford I, et al. Prolonged release melatonin in the treatment of primary insomnia: Evaluation of the age cut-off for short- and long-term response. Current Medical Research and Opinion. 2011 ; 27: 87-98
41. Wade AG, Ford I, Crawford G, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: Quality of sleep and next-day alertness outcomes. Curr Med Res Opin. 2007 ; 23: 2597-2605
42. Wade AG, Ford I, Crawford G, et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: A randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med. 2010 ; 8: 51
43. Walsh JK, Deacon S, Dijk DJ, et al. The selective extrasynaptic GABAA agonist, gaboxadol, improves traditional hypnotic efficacy measures and enhances slow wave activity in a model of transient insomnia. Sleep. 2007 ; 30: 593-602
44. Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010 ; 24: 1577-1601
45. Winsky-Sommerer R. Role of GABAA receptors in the physiology and pharmacology of sleep. Eur J Neurosci. 2009 ; 29: 1779-1794
46. Wyatt JK, Dijk DJ, Ritz-De Cecco A, et al. Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep. 2006 ; 29: 609-618